Lyell Immunopharma, Inc.

NASDAQ:LYEL

0.41 (USD) • At close May 21, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2025 Q12024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q1
Revenue 0.0070.0110.0340.0130.0030.0130.0250.0270.0650.0480.00335.7410.5532.8222.7552.6282.4452.3121.073.1181.256
Cost of Revenue 05.02604.9015.0245.0575.1044.5395.0274.5924.1723.733.9733.99002.9980000
Gross Profit 0-5.0150.034-4.888-5.021-5.044-5.079-4.512-4.962-4.544-4.16932.011-3.42-1.1682.7552.628-0.5532.3121.073.1181.256
Gross Profit Ratio 0-455.9091-376-1,673.667-388-203.16-167.111-76.338-93.903-1,389.6670.896-6.184-0.41411-0.2261111
Reseach & Development Expenses 43.44748.66839.536.15337.62541.61943.84947.47144.630.03841.60743.71935.8319.28531.43346.44641.52935.0924.50197.15225.5
General & Administrative Expenses 14.04614.52211.76912.25613.49413.16715.50719.0319.2790.02626.08430.45434.42131.87321.24119.11216.83114.86913.579.5628.88
Selling & Marketing Expenses 000000000000000000000
SG&A 14.04614.52211.76912.25613.49413.16715.50719.0319.2790.02626.08430.45434.42131.87321.24119.11216.83114.86913.579.5628.88
Other Expenses 0137.968-0.73-0.6451.09-0.5061.578-0.326-1.2880.004-1.251-0.014-1.122-0.0440.016-0.106-0.0270.0460.0280.0291.423
Operating Expenses 57.493201.15850.53948.40951.11954.78659.06465.93262.6210.06866.4473.00269.12950.3651.91665.33557.81541.83637.913105.68434.26
Operating Income -0.119-201.147-50.505-53.297-56.14-59.83-59.039-65.905-62.556-0.008-66.437-37.261-68.576-47.538-49.161-62.707-55.37-39.524-36.843-102.566-33.004
Operating Income Ratio -17-18,286.091-1,485.441-4,099.769-18,713.333-4,602.308-2,361.56-2,440.926-962.4-0.174-22,145.667-1.043-124.007-16.845-17.844-23.861-22.646-17.095-34.433-32.895-26.277
Total Other Income Expenses Net -52.0769.2125.9225.719-5.0926.1418.1862.015-4.4036.387-3.8170.9380.348-37.1420.2860.1120.3270.6671.1241.913.764
Income Before Tax -52.195-191.935-44.583-45.809-60.667-52.93-50.853-63.89-66.959-0.008-70.254-36.323-68.144-83.706-48.875-62.595-55.043-38.857-35.719-100.656-29.24
Income Before Tax Ratio -7,456.429-17,448.636-1,311.265-3,523.769-20,222.333-4,071.538-2,034.12-2,366.296-1,030.138-0.174-23,418-1.016-123.226-29.662-17.74-23.818-22.512-16.807-33.382-32.282-23.28
Income Tax Expense 00004.9815.013-6.608-2.34165.671-2.4473.817-0.952-0.432-0.323-0.27-0.218-0.354-1.288-1.096-1.881-2.341
Net Income -52.195-191.935-44.583-45.809-60.667-52.93-50.853-63.89-132.632.439-74.071-36.323-67.712-83.706-48.875-62.595-55.043-38.857-35.719-100.656-29.24
Net Income Ratio -7,456.429-17,448.636-1,311.265-3,523.769-20,222.333-4,071.538-2,034.12-2,366.296-2,040.46250.399-24,690.333-1.016-122.445-29.662-17.74-23.818-22.512-16.807-33.382-32.282-23.28
EPS -0.18-0.73-0.17-0.18-0.24-0.21-0.2-0.26-0.530.01-0.3-0.15-0.28-0.35-0.2-1.47-0.23-0.18-0.17-0.48-0.14
EPS Diluted -0.18-0.73-0.17-0.18-0.24-0.21-0.2-0.26-0.530.01-0.3-0.15-0.28-0.35-0.2-1.47-0.23-0.18-0.17-0.48-0.14
EBITDA -0.119-57.64-45.825-46.627-50.551-54.014-53.935-60.843-57.529-9.743-61.816-33.09-64.171-41.999-45.07-59.697-53.412-38.072-35.739-101.604-32.228
EBITDA Ratio -17-5,240-1,347.794-3,586.692-16,850.333-4,154.923-2,157.4-2,253.444-885.062-201.36-20,605.333-0.926-116.042-14.883-16.359-22.716-21.845-16.467-33.401-32.586-25.659